Extensive research has demonstrated that GHRH antagonists exert their antitumor effects by binding to GHRH receptors expressed on tumor cells, thereby blocking GHRH-mediated signaling pathways involved in tumor growth, invasion, and survival [8, 9, 60, 61]. Here, GHRHR is linked to neoplasm.